Collectively, these results demonstrated the ability of NPTyr-C9AP to specifically express CXCL9 and αPD-L1 in melanoma, laying the foundation for the recruitment and activation of T cells for enhanced antimelanoma immunotherapy. The gene discussed is CXCL9; the disease is melanoma.